How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu; Filippo De Braud; Giuseppe Lo Russo; Laura Concas; Daniela Femia; Claudio Vernieri; Alice Indini; Barbara Formisano; Roberto Buzzoni

doi:10.18632/oncotarget.8601

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Oncotarget. 2016 Jul 12;7(28):44841-44847. doi: 10.18632/oncotarget.8601.

Authors

Sara Pusceddu^{1

2}, Filippo De Braud^{1

2}, Giuseppe Lo Russo^{1

2}, Laura Concas^{1

2}, Daniela Femia^{1

2}, Claudio Vernieri^{1

2}, Alice Indini^{1

2}, Barbara Formisano^{1

2}, Roberto Buzzoni^{1

2}

Affiliations

¹ Medical Oncology Department, ENETs Center of Excellence, Milan, Italy.
² Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Abstract

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.

Keywords: everolimus; neuroendocrine tumors.

Publication types

Review
Systematic Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Everolimus / administration & dosage
Everolimus / therapeutic use*
Humans
Neuroendocrine Tumors / drug therapy*
Octreotide / administration & dosage
Outcome Assessment, Health Care / methods
Outcome Assessment, Health Care / statistics & numerical data
Randomized Controlled Trials as Topic
Survival Analysis

Substances

Everolimus
Octreotide